Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA reviewer guidance spells out "major and minor" PMA (premarket approval) faults

This article was originally published in Clinica

Executive Summary

The FDA has updated the guidance it uses to help staff decide whether a premarket approval application should be accepted for review. When PMAs are submitted to the agency, they are not automatically filed with the agency and assigned to a reviewer. The agency must first determine whether the application is ready for review, a process that can take up to 30 days.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT062049

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel